Cell therapy (Stem-cell derived) · developed by Longeveron
Allogeneic MSC is an allogeneic bone marrow-derived mesenchymal stromal cell formulation. It is being studied in mild Alzheimer's disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05233774 | Phase 2 | Mild Alzheimer's Disease | Completed | LGVN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mild Alzheimer's Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the LGVN page.
See LGVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LGVN catalysts and pipeline →